Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study.
Ana I Sánchez-FructuosoAndrea Bedia RabaEduardo Banegas DerasLuis A Vigara SánchezRosalía Valero San CecilioAntonio Franco EsteveLeonidas Cruzado VegaEva Gavela MartínezMaría E González GarciaPablo Saurdy CoronadoNancy D Valencia MoralesSofía Zarraga LarrondoNatalia Ridao CanoAuxiliadora Mazuecos BlancaDomingo Hernández MarreroIsabel Beneyto CastelloJavier Paul RamosAdriana Sierra OchoaCarmen Facundo MolasFrancisco González RonceroArmando Torres RamírezSecundino Cigarrán GuldrisIsabel Pérez FloresPublished in: Clinical kidney journal (2023)
SGLT2is in kidney transplant offer benefits in terms of controlling glycaemia, weight, blood pressure, anaemia, proteinuria and serum uric acid and magnesium. UTI was the most frequent adverse effect. According to our findings, these agents should be prescribed with caution in female DKTRs and those with a history of UTI.
Keyphrases
- uric acid
- blood pressure
- metabolic syndrome
- urinary tract infection
- type diabetes
- cardiovascular disease
- weight loss
- glycemic control
- physical activity
- hypertensive patients
- cross sectional
- weight gain
- stem cells
- blood glucose
- insulin resistance
- adverse drug
- bone marrow
- skeletal muscle
- mesenchymal stem cells
- smoking cessation